HMN-214

HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

Product Specifications

CAS Number

[173529-46-9]

Product Name Alternative

IVX-214

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/HMN-214.html

Purity

99.94

Solubility

DMSO : 8.33 mg/mL (ultrasonic)

Smiles

CC(N(S(=O)(C1=CC=C(OC)C=C1)=O)C2=CC=CC=C2/C=C/C3=CC=[N+]([O-])C=C3)=O

Molecular Formula

C22H20N2O5S

Molecular Weight

424.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Takagi M, et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs. 2003 Nov;21 (4) :387-99.|[2]Garland LL, et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12 (17) :5182-9.|[3]Tanaka H, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003 Oct 15;63 (20) :6942-7.|[4]Christensen MD, et al. Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. J Control Release. 2015 Apr 28;204:20-9.